Volume 6.47 | Dec 1

Hematopoiesis News 6.47 December 1, 2015
Hematopoiesis News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
Discovery of an Embryonic Switch for Cancer Stem Cell Generation
Scientists found that in cell and mouse models, a treatment that employed a targeted monoclonal antibody effectively impaired the ability of cancer stem cells to regenerate and made them easier to eradicate with existing enzyme-targeted therapies. The discovery suggests the basis for a potential new therapeutic approach to eradicate blood cancers. [Press release from UC San Diego discussing online prepublication in Proceedings of the National Academy of Sciences] Press Release | Abstract
New Cell Separation Kits to Isolate 90% Pure CD34+ Cells from Cord Blood. See the data and learn more here!
PUBLICATIONS (Ranked by impact factor of the journal)
Transcriptional Heterogeneity and Lineage Commitment in Myeloid Progenitors
The authors comprehensively mapped myeloid progenitor subpopulations by transcriptional sorting of single cells from bone marrow. They describe multiple progenitor subgroups, showing unexpected transcriptional priming toward seven differentiation fates but no progenitors with a mixed state. [Cell]
Abstract | Graphical Abstract

The Dlk1-Gtl2 Locus Preserves LT-HSC Function by Inhibiting the PI3K-mTOR Pathway to Restrict Mitochondrial Metabolism
Investigators showed that the Dlk1-Gtl2 locus plays a critical role in preserving long-term repopulating hematopoietic stem cells (LT-HSCs). [Cell Stem Cell] Abstract | Graphical Abstract

STAT5-Regulated microRNA-193b Controls Hematopoietic Stem and Progenitor Cell Expansion by Modulating Cytokine Receptor Signaling
Researchers showed a regulatory circuit that prevents excessive hematopoietic stem cell self-renewal by upregulation of miR-193b upon self-renewal promoting thrombopoietin-MPL-STAT5 signaling. [Nat Commun] Full Article

Microenvironmental Hypoxia Regulates FLT3 Expression and Biology in AML
Investigators showed that 25% of acute myeloid leukemia patients (AML) down-regulate Fms-like tyrosine kinase 3 (FLT3) expression on blasts in response to in vitro hypoxia, which was independent of its mutational state. [Sci Rep] Full Article

RNA-Based, Transient Modulation of Gene Expression in Human Hematopoietic Stem and Progenitor Cells
The authors provide a broad-ranging comparison of transfection methods for hard-to-transfect cells and offer new opportunities for DNA-free, non-integrating gene modulation in hematopoietic stem and progenitor cells. [Sci Rep] Full Article

Deoxycytidine Kinase Is Downregulated under Hypoxic Conditions and Confers Resistance against Cytarabine in Acute Myeloid Leukemia
Researchers investigated the impact of hypoxic versus normoxic conditions on the sensitivity of acute myeloid leukemia (AML) cell lines and primary AML blasts to cytarabine. [Eur J Haematol] Abstract


Novel Disease Burden Assessment Predicts Allogeneic Transplantation Outcomes in Myelodysplastic Syndrome
Scientists analyzed hematopoietic cell transplantation outcomes by time of transplant disease variables, including blast percentage, percentage of cytogenetically abnormal cells and Revised International Prognostic Scoring System cytogenetic classification. [Bone Marrow Transplant] Abstract

Impact of Conditioning with TBI in Adult Patients with T-Cell ALL Who Receive a Myeloablative Allogeneic Stem Cell Transplantation: A Report from the Acute Leukemia Working Party of EBMT
With an overall follow-up of 58 months, 523 patients received a TBI-based regimen, whereas 78 patients received a chemotherapy-based regimen including IV busulfan–cyclophosphamide. Unlike patients >35 years, patients aged <35 years who received a TBI-based regimen displayed an improved outcome compared with patients who received a chemotherapy-based regimen [Bone Marrow Transplant] Abstract

Ferritin as an Early Marker of Graft Rejection after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients
The authors analyzed ferritin plasma concentrations of 138 pediatric patients after hematopoietic stem cell transplantation. In 24 of the 27 pediatric patients with graft rejection, a significant increase of ferritin levels was observed 1 to 7 days prior to and at the time of graft rejection. [Ann Hematol] Abstract

Learn more about our standardized tools for cord blood banking.
The Multifaceted Functions of C/EBPα in Normal and Malignant Hematopoiesis
The authors summarize the current knowledge on the functions of CCAAT/enhancer binding protein alpha (C/EBPα) during normal and malignant hematopoiesis with special emphasis on the recent work. [Leukemia] Abstract

Long Non-Coding RNAs in Hematopoietic Malignancies
The authors focus on long non-coding RNAs that have been implicated in the pathogenesis of hematopoietic malignancies. [Brief Funct Genomics] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
SELLAS Life Sciences Reports Positive WT1 Cancer Vaccine Clinical Results in Mesothelioma and Acute Myeloid Leukemia (AML) Patients
SELLAS Life Sciences Group announced that positive data from the company’s clinical studies of its WT1 cancer vaccine in patients with malignant pleural mesothelioma and AML were reported. [Press release from SELLAS Life Sciences Group discussing research presented at the International WT1 Conference, Kyoto] Press Release

Bristol-Myers Squibb to Present New Data across Multiple Blood Cancers
Bristol-Myers Squibb will present data for elotuzumab in patients with relapsed or refractory (R/R) multiple myeloma; for Opdivo for investigational use in patients with R/R classical Hodgkin lymphoma; and for Sprycel in chronic myeloid leukemia. [Press release from Bristol-Myers Squibb Company discussing research to be presented at the 57th American Society of Hematology (ASH) Annual Meeting, Orlando] Press Release

From our sponsor:
Optimize your ALDHbr cell detection with tissue-specific ALDEFLUOR™ protocols.
Watch the video.
FDA Approves Empliciti, a New Immune-Stimulating Therapy to Treat Multiple Myeloma
The U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. [U.S. Food and Drug Administration] Press Release

Seattle Genetics Initiates Phase I/II Clinical Trial of SGN-CD33A (Vadastuximab Talirine) Before or After Allogeneic Stem Cell Transplant in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Seattle Genetics, Inc. announced initiation of a Phase I/II clinical trial of SGN-CD33A (vadastuximab talirine) in patients with relapsed or refractory acute myeloid leukemia (AML). [Seattle Genetics (BusinessWire)] Press Release

BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions
BioLineRx Ltd. announced that it has commenced a Phase I/II trial for BL-8040, in combination with standard of care immunosuppressive therapy, as a novel treatment for two bone marrow failure conditions: hypoplastic myelodysplastic syndrome and aplastic anemia. [BioLineRx Ltd.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Standardization of the Hematopoietic Progenitor Assay Training Course
February 17-18, 2016
Dresden, Germany

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Postdoctoral Fellow – Leukemia and Lymphoma (Emory University)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Team Leader/Professor/Associate Professor – Regenerative Medicine (Ji Nan University)

Postdoctoral Researcher – Cardiovascular/Hematopoietic Development (Kumamoto University)

Postdoctoral Fellow – Leukemia Research (City of Hope)

Postdoctoral Position – Stem Cells and Leukemia (Florida State University)

Assistant or Associate Professor – Cell and Regenerative Biology (University of Wisconsin, Madison)

Postdoctoral Research Fellow – Medicinal Chemistry for Cancer Drug Discovery (University of Michigan)

Research Technician – Stem Cell and Gene Therapy (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us